CD3/CD19 negative hematopoietic stem cells ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 85 | Idiopathic interstitial pneumonia | 1 |
85. Idiopathic interstitial pneumonia
Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03500731 (ClinicalTrials.gov) | April 19, 2018 | 30/3/2018 | Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure | Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure | Idiopathic Pulmonary Fibrosis;Emphysema or COPD | Biological: CD3/CD19 negative hematopoietic stem cells;Drug: Rituximab;Drug: Alemtuzumab;Drug: Fludarabine;Drug: Thiotepa;Drug: G-CSF;Drug: Hydroxyurea | Paul Szabolcs | NULL | Recruiting | 18 Years | 60 Years | All | 8 | Phase 1/Phase 2 | United States |